Ulrich Kanter - Tecan Group President
| TCHBF Stock | USD 202.52 9.48 4.47% |
President
Mr. Ulrich Kanter was Executive Vice President, Head of the Division Development and Operations and Member of the Management Board at Tecan Group Ltd. since July 2014. From 1995 to 2000 he was Vice President, Operations and Global Supply Chain Manager at AVL Medizintechnik and from 2000 to 2014 he held diverse positions with increasing management responsibility at Roche Diagnostics, most recently as General Manager and Head of Research Development in Graz, Austria. He is Mechanical Engineer and holds a Diploma in Business Administration . since 2014.
| Age | 60 |
| Tenure | 11 years |
| Phone | 41 44 922 88 88 |
| Web | https://www.tecan.com |
Tecan Group Management Efficiency
The company has return on total asset (ROA) of 0.0488 % which means that it generated a profit of $0.0488 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0981 %, meaning that it generated $0.0981 on every $100 dollars invested by stockholders. Tecan Group's management efficiency ratios could be used to measure how well Tecan Group manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Betty Larson | Becton Dickinson and | 44 | |
| David Montecalvo | West Pharmaceutical Services | 54 | |
| Thomas Spoerel | Becton Dickinson and | 46 | |
| Andy Polywacz | West Pharmaceutical Services | N/A | |
| Keith Holliday | STAAR Surgical | 62 | |
| James Lim | Becton Dickinson and | 56 | |
| Samuel Gesten | STAAR Surgical | 62 | |
| David Hickey | Becton Dickinson and | 60 | |
| Alexandre Conroy | Becton Dickinson and | 57 | |
| Silji Abraham | West Pharmaceutical Services | 53 | |
| George Miller | West Pharmaceutical Services | 64 | |
| Chad Winters | West Pharmaceutical Services | 45 | |
| James Borzi | Becton Dickinson and | 49 | |
| Aileen RuffPatry | West Pharmaceutical Services | N/A | |
| Eric Resnick | West Pharmaceutical Services | 55 | |
| Richard McHale | ResMed Inc | 54 | |
| Patrick Kaltenbach | Becton Dickinson and | 56 | |
| Quintin Lai | West Pharmaceutical Services | 53 | |
| Christopher Ryan | West Pharmaceutical Services | 63 | |
| Robert Douglas | ResMed Inc | 64 | |
| Jim Hollingshead | ResMed Inc | 57 | |
Management Performance
| Return On Equity | 0.0981 | |||
| Return On Asset | 0.0488 |
Tecan Group Leadership Team
Elected by the shareholders, the Tecan Group's board of directors comprises two types of representatives: Tecan Group inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tecan. The board's role is to monitor Tecan Group's management team and ensure that shareholders' interests are well served. Tecan Group's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tecan Group's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Achim Leoprechting, Executive Vice President Head of the Partnering Business division, Member of the Management Board | ||
| Wael Yared, Ex CTO | ||
| Ralf Griebel, Head VP | ||
| Andreas Wilhelm, Executive VP, General Counsel, Secretary and Member of Management Board | ||
| Martin Brandle, Sr Board | ||
| MBA MSc, Member VP | ||
| Gunter Weisshaar, Head VP | ||
| Ulrich Kanter, Executive Vice President Head of the Division Development and Operations, Member of the Management Board |
Tecan Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Tecan Group a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0981 | |||
| Return On Asset | 0.0488 | |||
| Profit Margin | 0.1 % | |||
| Operating Margin | 0.12 % | |||
| Current Valuation | 5.68 B | |||
| Shares Outstanding | 12.73 M | |||
| Shares Owned By Insiders | 0.37 % | |||
| Shares Owned By Institutions | 71.47 % | |||
| Price To Earning | 36.37 X | |||
| Price To Book | 3.63 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Tecan Pink Sheet
Tecan Group financial ratios help investors to determine whether Tecan Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Tecan with respect to the benefits of owning Tecan Group security.